1Droumaguet C,Balkau B,Simon D,et al.Use of HbAlc in predicting progression to diabetes in French men and women:data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR).Diabetes Care,2006,29:1619-1625.
2HAPO Study Cooperative Research Group,Metzger BE,Lowe LP,et al.Hyperglycemia and adverse pregnancy outcomes.N Engl J Med,2008,358:1991-2002.
3van den Berg,he G,Wouters P,Weekers F,et al.Intensive insulin therapy in the critically ill patients.N Engl J Med,2001,345:1359-1367.
4Antithrombotic Trialists' (ATT) Collaboration.Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials.Lancet,2009,373:1849-1860.
5Ogawa H,Nakayama M,Morimoto T,et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2diabetes:a randomized controlled trial.JAM A,2008,300:2134-2141.
6Belch J,MacCuish A,Campbell I,et al.The prevention of progression of arterial disease and diabetes (POPADAD) trial:factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.BMJ,2008,337:a1840.
7Coleman K,Austin BT,Brach C,et al.Evidence on the chronic care model in the new millennium.Health Aff (Millwood),2009,28:75-85.
8Borch-Johnsen K,Colagiuri S.DETECT-2:early detection of type 2 diabetes and IGT.Diabetes Voice,2003,48(4):11-13.
